The biopharma firm reported a Q2 net loss of $0.10 per share as cash reserves stood at $7.9 million.
Vyome Holdings, Inc. (HIND) reported a Q2 net loss of $720,000, or $0.10 per basic and diluted share, for the quarter ended June 30, 2026. The loss reflects ongoing operational expenses amid clinical development phases.
Cash and cash equivalents totaled $7.9 million as of the quarter’s end, providing runway for near-term initiatives. Prior quarter results and consensus estimates were not disclosed in the release.
No immediate market reaction was detailed in the announcement.